Innova Captab Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
INNOVACAP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts more than Nifty Microcap 250 and 1.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Innova Captab submitted its unaudited financial results for the quarter ended June 30, 2025, approved at a board meeting on August 7, 2025. On a consolidated basis, revenue from operations grew to ₹3,515.4 million from ₹2,942.7 million a year ago (up about 19.5%), while profit after tax rose modestly to ₹310.2 million from ₹294.8 million, with EPS at ₹5.42 versus ₹5.15. On a standalone basis, revenue jumped to ₹2,869.8 million from ₹2,268.3 million (up roughly 26.5%), but standalone PAT slipped to ₹203 million from ₹223.4 million and EPS fell to ₹3.55 from ₹3.90. Statutory auditor B S R & Co. LLP gave an unmodified (clean) limited review conclusion on both sets of results. The board also approved the purchase of a land property, with further updates to follow once the sale agreement is signed.
Strong topline growth, particularly on a standalone basis, signals healthy demand for the pharma business, though higher employee and other expenses squeezed standalone margins this quarter. The proposed land purchase points to capacity expansion plans, which is mildly positive if funded prudently; near-term stock reaction may depend on margin trends and the size of the land deal once disclosed.